Biotechnology
Medical
Pharmaceutical
Rigel Pharmaceuticals
$2.449876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.04 (-1.61%) Today
-$0.04 (-1.61%) Today
Why Robinhood?
You can buy or sell RIGL and other stocks, options, ETFs, and crypto commission-free!
About
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. Read More The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Employees
158
Headquarters
South San Francisco, California
Founded
1996
Market Cap
414.59M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.63M
High Today
$2.52
Low Today
$2.43
Open Price
$2.50
Volume
247.44K
52 Week High
$4.68
52 Week Low
$1.96
Collections
Biotechnology
Medical
Pharmaceutical
Therapy
Health
Technology
News
PR Newswire4h
Rigel Welcomes Jane Wasman to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of experience in the biopharma industry working with both large, multinational corporations and privately held start-ups. Her expertise includes strategic development, corporate governance, litigation, commercialization, compliance and government affairs, as well as operational im...
Simply Wall StMar 13
How Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Can Impact Your Portfolio Volatility
If you own shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The second sort is cause...
MarketBeatMar 2
Stock Price, News, & Analysis for Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeu...
Price Paid on Robinhood
11% Lower
Right Now
52 Week Low
$1.96
Average Price Paid
$2.75
52 Week High
$4.68
Earnings
-$0.18
-$0.11
-$0.04
$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 30, After Hours